- Tytuł:
- Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
- Autorzy:
- Źródło:
- Dermatology and Therapy: Research, treatment and aesthetic interventions in dermatology. 13(7):1517-1534
Czasopismo naukowe